Basilea & Roche to jointly study novel treatment for urothelial cancer
Category: #health  By Nikita Chaurasia  Date: 2019-01-24
  • share
  • Twitter
  • Facebook
  • LinkedIn

Basilea & Roche to jointly study novel treatment for urothelial cancer

The planned study would assess the efficacy, tolerability, and safety of the derazantinib-atezolizumab combination in patients with confirmed FGFR genomic aberrations and advanced urothelial cancer.

Basilea Pharmaceutica Limited, a commercial stage biopharmaceutical company, has reportedly announced a partnership with Roche to discover a combination of Roches PD-L1-blocking immune-checkpoint inhibitor atezolizumab (Tecentriq®) and Basileas derazantinib for people suffering from urothelial cancer.

Chief Medical Officer of Basilea Pharmaceutica Ltd, Dr. Marc Engelhardt was reportedly quoted saying that the firm is delighted to collaborate with Roche as the looks forward to explore a unique targeted treatment approach which addresses the high medical need of patients suffering from urothelical cancer. The combination of atezolizumab and derazantinib is based on a sound scientific rationale. Moreover, derazantinib has the capacity to improve the response to atezolizumab's immune-checkpoint inhibition.

For the uninitiated, derazantinib is called a panFGFR kinase inhibitor as it is known to be an investigational orally administered small molecule inhibitor of the FGFR family of kinases with strong activity against FGFR1, 2, and 3.

According to a press release by Basilea Pharmaceutica, the planned study would assess the efficacy, tolerability, and safety of the derazantinib-atezolizumab combination in patients with confirmed FGFR genomic aberrations and advanced urothelial cancer. Roche would provide clinical supply of atezolizumab and Basilea will be sponsoring the study, cite reliable sources.

Reportedly, the combination of inhibiting FGFR while, at the same time, improving T cell-mediated antitumor effects via CSF1R inhibition is potentially a promising new treatment approach in patients suffering from urothelial cancer.

For the record, urothelial cancer is the sixth most common cancer in the United States. These cancers begin in the urothelial cells that line the inside of the bladder. About 80,000 new cases of bladder cancer registered in the nation in the year 2017.

Sources familiar with the development claim that Basilea anticipates to begin a biomarker-driven multi-cohort phase 1/2 study by mid-2019.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

No more fake news with new ‘Search the Web’ feature on WhatsApp
No more fake news with new ‘Search the Web’ feature on WhatsApp
By Nikita Chaurasia

WhatsApp Inc., the Facebook owned messaging giant headquartered in California, has recently rolled out a new feature that allows the users on its messaging platform to search the web and verify the credibility of certain forwarded messages flagged by...

Hobbycraft reveals 200% upturn in online sales amid COVID-19 outbreak
Hobbycraft reveals 200% upturn in online sales amid COVID-19 outbreak
By Nikita Chaurasia

U.K.-based arts & crafting products supplier Hobbycraft has reportedly revealed a 200% growth in internet sales since the emergence of the COVID-19 pandemic. The company claimed that their consumer base has expanded remarkably since people are pr...

Nigeria gives green light to N8.64bn fund for Siemens electricity deal
Nigeria gives green light to N8.64bn fund for Siemens electricity deal
By Nikita Chaurasia

Federal Executive Council of Nigeria has reportedly authorized President Mohammadu Buhari’s initiative to release €15.21 million (N8,648,081,465.2) or N1.708 billion in onshore and N6,940,081,465.20 in offshore as counterpart funding for t...